These preclinical studies predict that sGC stimulators can reduce pulmonary vascular resistance (PVR) and NT-proBNP as well as improve exercise tolerance in patients with PAH, providing the basis for regulatory approval of riociguat in patients with PAH. Here, SGCB is linked to pulmonary arterial hypertension.